Nanosonics Limited (ASX:NAN): FY26 Infection Prevention Results and Ultrasound Disinfection

Aditi Sarkar

14 October 2026 12:24 AM AEDT

Nanosonics Limited (ASX:NAN): FY26 Infection Prevention Results and Ultrasound Disinfection

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FY26 revenue reached $203.9 million, reflecting 3% reported growth.
Global trophon installed devices reached 39,230 following a 6% increase.
Total trophon unit placements rose 9% to 4,230 in FY26.
The trophon platform uses sonically activated hydrogen peroxide for ultrasound probe disinfection.
The company advanced preparations for commercial introduction of its CORIS endoscope cleaning system.

Nanosonics Limited (ASX:NAN) develops infection prevention technologies for reprocessing reusable medical equipment, including its trophon ultrasound probe disinfection systems and CORIS endoscope cleaning platform. Its FY26 results, released in August 2026, showed a growing global trophon installed base alongside expenditure associated with developing and introducing another product platform. These activities shaped its performance.

How trophon Disinfects Ultrasound Probes

The trophon system uses sonically activated hydrogen peroxide to perform automated high-level disinfection of compatible ultrasound probes. During the process, the device produces an aerosol that contacts designated probe surfaces. After the disinfection cycle, hydrogen peroxide is converted into oxygen and water. Compatible probes and approved consumables remain essential.

For Nanosonics Limited (ASX:NAN), this process connects equipment sales to continued use of compatible disinfectant, chemical indicators and related services. Hospitals and other healthcare facilities must maintain infection prevention procedures, but actual consumption depends on device utilisation and clinical activity. The system’s disinfection purpose should not be confused with the diagnosis or treatment of disease.

FY26 Revenue and Installed Base

In the financial year ended 30 June 2026, Nanosonics Limited (ASX:NAN) reported revenue of $203.9 million, representing a 3% increase. On a constant-currency basis, the company reported revenue of $211.5 million, up 6%. The difference illustrates how exchange-rate movements affected the reported result. Neither measure should be read as a forecast of subsequent periods.

Total trophon unit placements increased 9% to 4,230 devices during FY26. The global cumulative installed base grew 6% to 39,230 devices. Nanosonics Limited (ASX:NAN) also recorded a 32% increase in North American upgrades, reflecting customer replacement activity alongside new placements. Upgrades and new placements are distinct activities.

The reported FY26 EBIT was $16.0 million, down 10%; at constant currency, EBIT was $21.6 million, up 21%. These are different presentations of the same performance. The company’s annual report also recorded cash and cash equivalents of $155.2 million at 30 June 2026, including the effects of capital allocation during the year.

CORIS Broadens the Reprocessing Portfolio

Alongside trophon, Nanosonics Limited (ASX:NAN) continued preparing its CORIS System for wider commercial use. CORIS addresses cleaning processes for flexible endoscopes, a different instrument category from ultrasound probes. The company stated in its FY26 results that its launch timetable was directed at the first half of FY27. Timing, customer uptake and the revenue contribution from the platform depend on implementation and commercial execution.

The platforms serve distinct reprocessing needs, with CORIS requiring further commercial rollout.

Operating Considerations and Risks

Nanosonics Limited (ASX:NAN) operates in a regulated medical-device environment where disinfection performance, product compatibility and procedural compliance matter. Deployment can also depend on healthcare capital budgets, equipment upgrade cycles and local purchasing arrangements. Foreign currency movements affect its translated financial results, while CORIS requires investment before its longer-term commercial contribution can be assessed.

Changes in infection prevention requirements, competing technologies or adoption rates may affect equipment demand and consumables usage. The company must also maintain manufacturing quality and customer support across its operating markets. These factors provide context for assessing the difference between FY26 reported outcomes and subsequent product introduction milestones.

Key Insights

Nanosonics Limited (ASX:NAN) combined FY26 trophon equipment placements and a larger global installed base with preparations to introduce CORIS. Revenue rose on both reported and constant-currency measures, while EBIT showed different movements under those measures. The available disclosures distinguish established disinfection operations from a developing second platform without establishing future financial outcomes.

FAQs

Q: What does Nanosonics manufacture?

A:It develops medical-device reprocessing technologies, including trophon ultrasound probe disinfection systems and the CORIS endoscope cleaning platform.

Q: How does trophon perform high-level disinfection?

A:The device uses a controlled process based on sonically activated hydrogen peroxide for compatible ultrasound probes.

Q: What was Nanosonics’ FY26 revenue?

A:Reported revenue for the year ended 30 June 2026 was $203.9 million.

Q: How many trophon devices were in the global installed base in FY26?

A:The company reported a cumulative installed base of 39,230 devices.

Q: Is CORIS the same product as trophon?

A:No. CORIS addresses flexible endoscope cleaning, whereas trophon is designed for ultrasound probe high-level disinfection.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.